SynthesisFrontiers in oncology2025
Global research trends in gastroenteropancreatic neuroendocrine tumors: a bibliometric analysis from 2000 to 2023.
Synthesis in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The incidence of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) is increasing. To improve patient outcomes, it is essential to develop integrated treatment strategies based on tumor characteristics. Researchers need a rapid visualization of global research trends in GEP-NETs. However, there is currently no bibliometric analysis of GEP-NETs available. This paper aims to fill this gap by using bibliometric methods to quantitatively visualize the current status and research hotspots of GEP-NETs from 2000 to 2023, thereby providing a reference for future research. Methods: We analyzed 1,140 English publications on GEP-NETs from 2000 to 2023, sourced from the Web of Science Core Collection (WOSCC). Microsoft Excel 2021, CiteSpace, and VOSviewer were used for bibliometric analysis and visualization. Results: From 2000 to 2023, the number of annual publications on GEP-NETs steadily increased. We identified 1,140 articles published in 401 journals by 5,751 authors from 55 countries. The United States emerged as a leading contributor to GEP-NETs research. Erasmus University Rotterdam, the journal Neuroendocrinology, and the author De Herder WW had the highest number of publications. The most frequently cited reference was by Dasari A. A co-word analysis of keywords revealed five research clusters within the field of GEP-NETs. Immunotherapy and peptide receptor radionuclide therapy (PRRT) are prominent research trends. The terms "carcinoid tumors" and "Lu 177 dotatate" showed significant burst strength. Conclusions: With the rising incidence of GEP-NETs, there is an increasing focus on their diagnosis and treatment. This bibliometric analysis spotlights the current status, key contributors, top journals, influential publications, and the trends of research topics on GEP-NETs. It provides a comprehensive overview of GEP-NETs research from 2000 to 2023. By providing this quantitative analysis, our study aims to guide future research efforts and support the development of more effective diagnosis and treatment strategies, ultimately advancing the field of GEP-NETs. Our study can help researchers understand global research trends and future directions in GEP-NETs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.